Mersana Therapeutics (MRSN) Revenue & Revenue Breakdown
Mersana Therapeutics Revenue Highlights
Latest Revenue (Y)
$36.85M
Latest Revenue (Q)
$12.60M
Mersana Therapeutics Revenue by Period
Mersana Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $36.85M | 38.65% |
| 2022-12-31 | $26.58M | 61716.28% |
| 2021-12-31 | $43.00K | -94.81% |
| 2020-12-31 | $828.00K | -98.03% |
| 2019-12-31 | $42.12M | 297.61% |
| 2018-12-31 | $10.59M | -39.62% |
| 2017-12-31 | $17.55M | -30.30% |
| 2016-12-31 | $25.17M | 142.99% |
| 2015-12-31 | $10.36M | - |
Mersana Therapeutics generated $36.85M in revenue during NA 2023, up 38.65% compared to the previous quarter, and up 347.89% compared to the same period a year ago.
Mersana Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $12.60M | 449.41% |
| 2024-06-30 | $2.29M | -75.20% |
| 2024-03-31 | $9.24M | -13.61% |
| 2023-12-31 | $10.70M | 39.01% |
| 2023-09-30 | $7.70M | -27.75% |
| 2023-06-30 | $10.65M | 36.55% |
| 2023-03-31 | $7.80M | -46.88% |
| 2022-12-31 | $14.69M | 163.56% |
| 2022-09-30 | $5.57M | 30.09% |
| 2022-06-30 | $4.28M | 110.41% |
| 2022-03-31 | $2.04M | 18409.09% |
| 2021-12-31 | $11.00K | - |
| 2021-09-30 | $11.00K | - |
| 2021-06-30 | $11.00K | - |
| 2021-03-31 | $11.00K | - |
| 2020-12-31 | $11.00K | - |
| 2020-09-30 | $11.00K | -98.62% |
| 2020-06-30 | $796.00K | 7136.36% |
| 2020-03-31 | $11.00K | -73.81% |
| 2019-12-31 | $42.00K | -95.02% |
| 2019-09-30 | $844.00K | 317.82% |
| 2019-06-30 | $202.00K | -99.51% |
| 2019-03-31 | $41.03M | 3354.12% |
| 2018-12-31 | $1.19M | -44.77% |
| 2018-09-30 | $2.15M | -48.68% |
| 2018-06-30 | $4.19M | 36.78% |
| 2018-03-31 | $3.06M | -6.04% |
| 2017-12-31 | $3.26M | -47.97% |
| 2017-09-30 | $6.27M | 68.15% |
| 2017-06-30 | $3.73M | -13.12% |
| 2017-03-31 | $4.29M | -64.24% |
| 2016-12-31 | $12.00M | 267.75% |
| 2016-09-30 | $3.26M | -47.51% |
| 2016-06-30 | $6.21M | 68.11% |
| 2016-03-31 | $3.70M | - |
Mersana Therapeutics generated $12.60M in revenue during Q3 2024, up 449.41% compared to the previous quarter, and up 118.25% compared to the same period a year ago.
Mersana Therapeutics Revenue Breakdown
Mersana Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 |
|---|---|---|
| Performance Obligations | $8.40M | $1.80M |
Latest
Mersana Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Performance Obligations (100.00%).
Mersana Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| RCUS | Arcus Biosciences | $117.00M | $48.00M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.67M |
| MRUS | Merus | $43.95M | $11.77M |
| MRSN | Mersana Therapeutics | $36.85M | $12.60M |
| RLAY | Relay Therapeutics | $25.55M | - |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| PLRX | Pliant Therapeutics | $1.58M | - |
| VRDN | Viridian Therapeutics | $314.00K | $86.00K |
| CGEM | Cullinan Oncology | - | - |
| XFOR | X4 Pharmaceuticals | - | $560.00K |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| TERN | Terns Pharmaceuticals | - | - |